Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: An integrated modelling approach

The Lancet Global Health

Volumn 2, Issue 10, 2014, Pages e581-e591

  Langley, Ivor ^a   Lin, Hsien Ho ^b   Egwaga, Saidi ^c   Doulla, Basra ^c   Ku, Chu Chang ^b   Murray, Megan ^d   Cohen, Ted ^d,e   Squire, S Bertel ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c National Programme on Tuberculosis and Leprosy   (Tanzania)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISABILITY ADJUSTED LIFE YEAR; FALSE POSITIVE RESULT; FLUORESCENCE MICROSCOPY; FOLLOW UP; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; LIGHT EMITTING DIODE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT ASSESSMENT; PREDICTIVE VALUE; PREVALENCE; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; STAINING; TANZANIA; TUBERCULOSIS; XPERT MTB RIF TEST; ZIEHL NEELSEN STAINING; ALGORITHM; ANTIBIOTIC RESISTANCE; COST BENEFIT ANALYSIS; DEVICES; ECONOMICS; GOVERNMENT; MICROBIOLOGY; SPUTUM; STATISTICAL MODEL; TIME;

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ALGORITHMS; ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, BACTERIAL; GOVERNMENT PROGRAMS; HUMANS; MICROSCOPY, FLUORESCENCE; MODELS, ECONOMETRIC; RIFAMPIN; SPUTUM; TANZANIA; TIME FACTORS; TUBERCULOSIS;

EID: 84907262438     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(14)70291-8     Document Type: Article

References (48)

1. Same-day diagnosis of tuberculosis by microscopy: policy statement 2011, WHO, World Health Organization, Geneva.
2. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update 2013, WHO, World Health Organization, Geneva.
3. Rapid implementation of the Xpert MTB/RIF diagnostic test 2011, WHO, World Health Organization, Geneva.
4. Cobelens F, van den Hof S, Pai M, Squire SB, Ramsay A, Kimerling ME Which new diagnostics for tuberculosis, and when?. J Infect Dis 2012, 205(suppl 2):S191-S198.
5. Squire SB, Ramsay AR, van den Hof S, et al. Making innovations accessible to the poor through implementation research. Int J Tuberc Lung Dis 2011, 15:862-870.
6. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010, 363:1005-1015.
7. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011, 377:1495-1505.
8. Cuevas LE, Al-Sonboli N, Lawson L, et al. LED fluorescence microscopy for the diagnosis of pulmonary tuberculosis: a multi-country cross-sectional evaluation. PLoS Med 2011, 8:e1001057.
9. Cuevas LE, Yassin MA, Al-Sonboli N, et al. A multi-country non-inferiority cluster randomized trial of frontloaded smear microscopy for the diagnosis of pulmonary tuberculosis. PLoS Med 2011, 8:e1000443.
10. Epidemiological factsheet: Tanzania 2011, UNAIDS, WHOWHO, UNAIDS, Geneva.
11. Global tuberculosis report 2012 2012, WHO, World Health Organization, Geneva.
12. Operational guidelines for the management of drug resistant TB in Tanzania United Republic of Tanzania Ministry of Health and Social Welfare Tanzania, (accessed Sept 3, 2014). http://ntlp.go.tz/index.php?option=com_phocadownload&view=category&id=6:manual-and-guidelines&Itemid=139.
13. Lin HH, Langley I, Mwenda R, et al. A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools. Int J Tuberc Lung Dis 2011, 15:996-1004.
14. Treatment of tuberculosis guidelines 2010, WHO, World Health Organization, Geneva. 4th edn.
15. Manual of the National Tuberculosis and Leprosy Programme 2006, National Tuberculosis and Leprosy Programme of Tanzania, National Tuberculosis and Leprosy Programme of Tanzania, Dar es Salaam, Tanzania.
16. Günal MPM Discrete event simulation for performance modelling in health care: a review of the literature. J Simulation 2010, 4:42-51.
17. Katsaliaki KMN Applications of simulation research within the healthcare context. J Oper Res Soc 2011, 62:1431-1451.
18. Dye C, Garnett GP, Sleeman K, Williams BG Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 1998, 352:1886-1891.
19. Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci USA 2008, 105:11293-11298.
20. Lin HH, Dowdy D, Dye C, Murray M, Cohen T The impact of new tuberculosis diagnostics on transmission: why context matters. Bull World Health Org 2012, 90:739. 47A.
21. Poole DRA Inference for deterministic simulation models: the Bayesian melding approach. J Am Stat Assoc 2000, 95:1244-1255.
22. The United Republic of Tanzania Ministry of Health and Social Welfare National Tuberculosis and Leprosy Programme annual report National TB and Leprosy Programme, Ministry of Health and Social WelfareMinistry of Health and Social Welfare, (accessed Sept 3, 2014). http://ntlp.go.tz/index.php?option=com_phocadownload&view=category&id=10:annual-reports&Itemid=139.
23. Squire SB, Belaye AK, Kashoti A, et al. 'Lost' smear-positive pulmonary tuberculosis cases: where are they and why did we lose them?. Int J Tuberc Lung Dis 2005, 9:25-31.
24. Swai HF, Mugusi FM, Mbwambo JK Sputum smear negative pulmonary tuberculosis: sensitivity and specificity of diagnostic algorithm. BMC Res Notes 2011, 4:475.
25. Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis: policy statement 2011, WHO, World Health Organization, Geneva.
26. Steingart KR, Sohn H, Schiller I, et al. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013, 1. CD009593.
27. Negotiated prices for Xpert® MTB/RIF and FIND country list Diagnostics FfIN, (accessed Sept 3, 2014). http://www.finddiagnostics.org/about/what_we_do/successes/find-negotiated-prices/xpert_mtb_rif.html.
28. The cost of comprehensive HIV treatment in Tanzania. Report of a cost study of HIV treatment programs in Tanzania 2011, Ministry of Health and Social Welfare Tanzania and US Centers for Disease Control and Prevention, Tanzanian Ministry of Health and Social Welfare, Dar es Salaam, Tanzania, Atlanta, GA, USA.
29. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009 2009, WHO, World Health Organization, Geneva.
30. Trunz BB, Fine P, Dye C Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367:1173-1180.
31. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999, 353:444-449.
32. Vynnycky E, Fine PE The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 1997, 119:183-201.
33. Cohen T, Lipsitch M, Walensky RP, Murray M Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci USA 2006, 103:7042-7047.
34. Hughes G, Currie C, Corbett EL. Modeling tuberculosis in areas of high HIV prevalence. Proceedings of the 38th Conference on Winter Simulation, 2006: 459-65.
35. Lawn SD, Churchyard G Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009, 4:325-333.
36. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012, 380:2129-2143.
37. Langley I, Doulla B, Lin HH, Millington K, Squire B Modelling the impacts of new diagnostic tools for tuberculosis in developing countries to enhance policy decisions. Health Care Manag Sci 2012, 15:239-253.
38. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2163-2196.
39. Mathers CD, Vos T, Lopez AD, Salomon J, Ezzati M National burden of disease studies: a practical guide 2001, World Health Organization, Geneva.
40. Gray AM, Clarke PM, Wolstenholme J, Wordsworth S Applied methods of cost-effectiveness analysis in healthcare 2010, Oxford University Press, Oxford.
41. World economic outlook database. International Monetary Fund International Monetary Fund, (accessed Sept 3, 2014). http://www.imf.org/external/pubs/ft/weo/2013/01/weodata/index.aspx.
42. Shillcutt SD, Walker DG, Goodman CA, Mills AJ Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 2009, 27:903-917.
43. Jaynes ET, Kempthorne O Confidence intervals vs Bayesian intervals. Foundations of probability theory, statistical inference, and statistical theories of science 1976, 175-257. D. Reidel Publishing Company, Dordrecht-Holland. W.L. Harper, C.A. Hooker (Eds.).
44. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2014, 383:424-435.
45. Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?. Lancet Infect Dis 2014, 14:527-532.
46. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 2011, 8:e1001120.
47. Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med 2012, 9:e1001347.
48. TB Modelling and Analysis Consortium (accessed Sept 3, 2014). http://tb-mac.org/Resources/Resource/5.